Apolipoprotein A-IV fibrils: structural diagnosis of mixed cardiac amyloidosis
Cardiac amyloidosis (CA) occurs when misfolded proteins deposit as fibrils in the extracellular space of the heart. The fibrillogenic properties of apolipoprotein A-IV (ApoAIV) have been histologically observed and associated with CA pathogenesis. We report the structure of an ApoAIV amyloid from a patient's heart, which coexist amongst transthyretin (TTR) amyloids. These cases of undetected mixed CA highlight the importance of developing broad-spectrum anti-amyloid treatments to improve outcomes in patients.
Authors
- Shintaro Aibara (ORCID: https://orcid.org/0000-0003-2221-482X)
- Monika Papworth
- Karin Klingel (ORCID: https://orcid.org/0000-0003-0203-2498)
- Edmond Wong
- Taianá Maia de Oliveira (ORCID: https://orcid.org/0000-0003-3231-8112)
- Hendrik Milting (ORCID: https://orcid.org/0000-0001-9722-0007)
- Magnus Althage (ORCID: https://orcid.org/0000-0001-9083-943X)
- Astrid Kassner
- Qing‐Dong Wang (ORCID: https://orcid.org/0000-0001-9570-4411)
- Cláudia Correia (ORCID: https://orcid.org/0000-0002-7257-9053)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Heart and Diabetes Center North Rhine-Westphalia (DE)
- University Children's Hospital Tübingen (DE)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1038/s41467-025-64902-0
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00